Vicki Ellingrod

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics
    Vicki L Ellingrod
    Department of Clinical Social and Administrative Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA
    J Clin Psychopharmacol 32:261-5. 2012
  2. ncbi request reprint Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia
    Vicki L Ellingrod
    Department of Psychiatry in the University of Michigan College of Pharmacy and College of Medicine, Ann Arbor, Michigan 48109, USA
    Psychopharmacol Bull 40:57-62. 2007
  3. pmc Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants
    Vicki L Ellingrod
    University of Michigan College of Pharmacy, Department of Clinical Sciences, School of Medicine, Ann Arbor 48109, USA
    Schizophr Res 98:47-54. 2008
  4. pmc Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs)
    Vicki L Ellingrod
    University of Michigan, College of Pharmacy, Department of Clinical Social and Administrative Sciences, 428 Church Street, Ann Arbor, Michigan 48109, USA
    Schizophr Res 130:20-6. 2011
  5. ncbi request reprint The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia
    Ying Chi Lin
    Department of Clinical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, 48109, USA
    Ther Drug Monit 28:668-72. 2006
  6. doi request reprint Antipsychotic-induced hyperprolactinemia
    Jolene R Bostwick
    Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan 48109, USA
    Pharmacotherapy 29:64-73. 2009
  7. doi request reprint Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions
    Kelan L H Thomas
    Clinical Pharmacogenomics Laboratory, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109 1065, USA
    Pharmacotherapy 29:822-31. 2009
  8. ncbi request reprint Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia
    Jeffrey R Bishop
    Psychiatr Genet 17:358. 2007
  9. ncbi request reprint Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia
    Jeffrey R Bishop
    Department of Pharmacy Practice, College of Pharmacy, University of Illinois, Chicago, IL, USA
    Med Sci Monit 12:BR47-50. 2006
  10. ncbi request reprint Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment
    Jeffrey R Bishop
    University of Iowa College of Pharmacy, Clinical and Administrative Division, S413 Pharmacy Building, Iowa City, IA 52242, USA
    Schizophr Res 77:253-60. 2005

Collaborators

Detail Information

Publications26

  1. pmc Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics
    Vicki L Ellingrod
    Department of Clinical Social and Administrative Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA
    J Clin Psychopharmacol 32:261-5. 2012
    ..Use of this information clinically may help to reduce the risk for AAP metabolic complications in those whose clinical care necessitates the use of AAPs...
  2. ncbi request reprint Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia
    Vicki L Ellingrod
    Department of Psychiatry in the University of Michigan College of Pharmacy and College of Medicine, Ann Arbor, Michigan 48109, USA
    Psychopharmacol Bull 40:57-62. 2007
    ..The objective of the current investigation was to determine the relationship between polymorphisms of the leptin system (leptin gene and leptin receptor) and olanzapine-induced weight gain in persons with schizophrenia...
  3. pmc Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants
    Vicki L Ellingrod
    University of Michigan College of Pharmacy, Department of Clinical Sciences, School of Medicine, Ann Arbor 48109, USA
    Schizophr Res 98:47-54. 2008
    ....
  4. pmc Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs)
    Vicki L Ellingrod
    University of Michigan, College of Pharmacy, Department of Clinical Social and Administrative Sciences, 428 Church Street, Ann Arbor, Michigan 48109, USA
    Schizophr Res 130:20-6. 2011
    ..This study examined the status of endothelial function within the schizophrenia population and determined pharmacogenetic, medication, dietary, and lifestyle factors associated with this functioning...
  5. ncbi request reprint The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia
    Ying Chi Lin
    Department of Clinical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, 48109, USA
    Ther Drug Monit 28:668-72. 2006
    ..The PGP C3435T genotype may help to determine positive symptom reduction from olanzapine clinically, but these findings should be replicated in a larger sample of subjects...
  6. doi request reprint Antipsychotic-induced hyperprolactinemia
    Jolene R Bostwick
    Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan 48109, USA
    Pharmacotherapy 29:64-73. 2009
    ..Additional research is needed to clarify the appropriate level of monitoring, the long-term effects, and the optimal treatment of antipsychotic-induced hyperprolactinemia...
  7. doi request reprint Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions
    Kelan L H Thomas
    Clinical Pharmacogenomics Laboratory, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109 1065, USA
    Pharmacotherapy 29:822-31. 2009
    ..As we appreciate the many pharmacologic mechanisms related to adverse drug reactions and gain polymorphic functional data, we will have opportunities to refine hypotheses for future pharmacogenetic association analyses...
  8. ncbi request reprint Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia
    Jeffrey R Bishop
    Psychiatr Genet 17:358. 2007
  9. ncbi request reprint Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia
    Jeffrey R Bishop
    Department of Pharmacy Practice, College of Pharmacy, University of Illinois, Chicago, IL, USA
    Med Sci Monit 12:BR47-50. 2006
    ..The purpose of this investigation was examine associations between the second messenger G-Protein Beta3 Subunit Gene (GNB3) C825T polymorphism and olanzapine response and weight gain treatment...
  10. ncbi request reprint Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment
    Jeffrey R Bishop
    University of Iowa College of Pharmacy, Clinical and Administrative Division, S413 Pharmacy Building, Iowa City, IA 52242, USA
    Schizophr Res 77:253-60. 2005
    ..The purpose of this study was to determine whether a pharmacogenetic relationship exists between six polymorphisms of GRM3 and clinical improvement during olanzapine treatment in persons with schizophrenia...
  11. ncbi request reprint The association of weight gain and olanzapine plasma concentrations
    Paul J Perry
    Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
    J Clin Psychopharmacol 25:250-4. 2005
    ..The association of weight gain with plasma concentrations during treatment with olanzapine may support the utilization of plasma drug concentration as a marker for antipsychotic-induced weight gain in the treatment of schizophrenia...
  12. ncbi request reprint Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine
    Vicki L Ellingrod
    University of Iowa, College of Pharmacy, Iowa, USA
    Am J Med Genet B Neuropsychiatr Genet 134:76-8. 2005
    ..Weight gain from atypical antipsychotic use has become a significant problem. Recent reports have liked the -759 polymorphism of the 5HT2C receptor and obesity as well as weight gain from chlorpromazine, risperidone, and clozapine...
  13. ncbi request reprint Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism
    Del D Miller
    Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242 1000, USA
    Am J Med Genet B Neuropsychiatr Genet 133:97-100. 2005
    ..Subjects without the -759T variant allele were at a greater risk for weight gain from clozapine over 6-months compared to those with the -759T allele...
  14. ncbi request reprint CYP2D6 polymorphisms and atypical antipsychotic weight gain
    Vicki L Ellingrod
    College of Pharmacy, University of Iowa, Iowa City, Iowa, USA
    Psychiatr Genet 12:55-8. 2002
    ..This may be due to increased olanzapine concentrations leading to increased exposure, which may trigger AAP weight gain...
  15. ncbi request reprint Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6
    Vicki L Ellingrod
    College of Pharmacy, University of Iowa, Iowa City 52242, USA
    Pharmacotherapy 22:1416-9. 2002
    ..To investigate the relationships between cytochrome P450 (CYP) 2D6 genotype, antipsychotic drug exposure, abnormal movements and tardive dyskinesia, and cigarette smoking...
  16. ncbi request reprint Distribution of the serotonin 2C (5HT2C) receptor gene -759C/T polymorphism in patients with schizophrenia and normal controls
    Vicki L Ellingrod
    College of Pharmacy, Clinical and Administrative Division, University of Iowa, Iowa City, USA
    Psychiatr Genet 14:93-5. 2004
    ....
  17. ncbi request reprint 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia
    Vicki L Ellingrod
    J Clin Psychopharmacol 22:622-4. 2002
  18. ncbi request reprint 5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia
    Vicki L Ellingrod
    Clinical and Administrative Division, University of Iowa College of Pharmacy, Iowa City, Iowa, USA
    Psychopharmacol Bull 37:109-12. 2003
    ..We conclude that the A/A genotype may be associated with olanzapine negative symptom response, seen as a 2-fold greater percent reduction in SANS, and may be clinically relevant...
  19. ncbi request reprint C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects
    David I Min
    Division of Clinical and Administrative Pharmacy, College of Pharmacy, The University of Iowa, 118 Pharmacy Building, Iowa City, IA 52242, USA
    Ther Drug Monit 24:400-4. 2002
    ..There were no statistical differences in cyclosporine pharmacokinetics among different MDR1 genotypes in these 14 healthy subjects...
  20. ncbi request reprint The influence of cognitive impairment and behavioral dysregulation on daily functioning in the nursing home setting
    Susan K Schultz
    Department of Psychiatry, University of Iowa College of Medicine, Iowa City, 52242 1000, USA
    Am J Psychiatry 160:582-4. 2003
    ..The influence of psychiatric symptoms and cognitive impairment on daily living skills was explored in a series of nursing home residents. Three categories of symptoms were examined: behavioral disturbances, depression, and delusions...
  21. ncbi request reprint The influence of cognitive impairment and psychiatric symptoms on daily functioning in nursing facilities: a longitudinal study
    Susan K Schultz
    Department of Psychiatry, University of Iowa College of Medicine, 500 Newton Road, Iowa City, Iowa 52242 1000, USA
    Ann Clin Psychiatry 14:209-13. 2002
    ..These findings may have implications for treatment interventions that seek to enhance functioning in the skilled nursing setting...
  22. ncbi request reprint Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects
    Jeffrey R Bishop
    University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA
    Neuropsychopharmacology 31:2281-8. 2006
    ..6; p=0.046). Furthermore, the 5HT2A -1438 GG genotype was a significant predictor of lower arousal scores (p=0.022) after accounting for other measures. There was no significant relationship between any outcome measure and GNB3 genotype...
  23. ncbi request reprint Phobic anxiety in late-life in relationship to cognition and 5HTTLPR polymorphism
    Susan K Schultz
    Psychiatr Genet 15:305-6. 2005
    ..However, in this sample we did not detect a significant association between phobic anxiety and the 5HTTLPR genotype. The interaction between age-related changes in cognition and anxiety remain an important area for future studies...
  24. ncbi request reprint Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response
    Jeffrey R Bishop
    University of Iowa College of Pharmacy, Clinical and Administrative Division, S413 Pharmacy Building, Iowa City, IA 52242 1112, USA
    Pharmacogenomics 5:463-77. 2004
    ....
  25. ncbi request reprint CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects
    David I Min
    Division of Clinical and Administrative Pharmacy, College of Pharmacy, The University of Iowa, Iowa City, Iowa, USA
    Ther Drug Monit 26:524-8. 2004
    ..In conclusion, the CYP3A5*3C polymorphism appears to affect AUC and CL/F of oral CsA significantly in healthy subjects, which may partly explain some of the differences of pharmacokinetics in CsA between African Americans and whites...
  26. ncbi request reprint Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis
    Vicki L Ellingrod
    College of Pharmacy, University of Iowa, Iowa City, USA
    Pharmacotherapy 22:1-5. 2002
    ..To compare the effects of risperidone and olanzapine on cognition in elderly patients with dementia and psychosis, and to compare the side effects of these drugs...